Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019

San Francisco, CA (UroToday.com) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced multiple data presentations from its prostate cancer and solid tumor portfolios will be featured at the European Society for Medical Oncology (ESMO) Annual Congress 2019, taking place September 27 to October 1 in Barcelona, Spain. Among Janssen's 12 accepted abstracts are an oral presentation reporting updated overall survival results from the ERLEADA® (apalutamide) Phase 3 SPARTAN study in patients with non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the ERLEADA® Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC), demonstrating preservation of overall health-related quality of life; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD).

"Janssen is focused on addressing areas of unmet need in both prostate cancer and solid tumors, and this year's ESMO Annual Congress provides an opportunity to share these important study results for both approved and investigational therapies," said Mark Wildgust, Ph.D., Vice President, Global Medical Affairs, Oncology, Janssen Research & Development, LLC. "In particular, we look forward to presenting new data for ERLEADA® and niraparib, which reinforce our continued commitment to improve outcomes for patients diagnosed with prostate cancer across the disease spectrum."

Company-sponsored abstracts to be presented at the meeting include:


Abstract No.

Title

Date/Time

ERLEADA® (apalutamide)

Oral Presentation

Abstract #843O
Apalutamide and Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
(nmCRPC): Updated Results from the Phase 3 SPARTAN Study

Friday,
September 27
2:39 PM - 2:51 PM CET

Poster Presentations

Abstract #851PD
Patient-Reported Outcomes (PROs) From TITAN: A Phase 3, Randomized, Double-Blind Study of
Apalutamide Versus Placebo Added to Androgen Deprivation Therapy in Patients with Metastatic
Castration-Sensitive Prostate Cancer (mCSPC)

Monday, September 30

12:00 PM CET

Abstract #883P
Androgen Receptor Aberrations in Patients with Metastatic Castration-Sensitive Prostate Cancer
(mCSPC) Treated with Apalutamide Plus Androgen Deprivation Therapy in TITAN

Monday, September 30

12:00 PM CET


Abstract #900TiP
A Phase 2 randomized, open-label study comparing salvage radiotherapy in combination with 6
months of androgen-deprivation therapy with LHRH agonist or antagonist versus anti-androgen
therapy with apalutamide in patients with biochemical progression after radical prostatectomy

Monday, September 30

12:00 PM CET

Niraparib

Poster Presentations

Abstract #LBA50
Pre-specified interim analysis of GALAHAD: A Phase 2 study of niraparib in patients with
metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects

Sunday, September 29

8:30 AM CET

Abstract #897TiP
A Phase 3 randomized, placebo-controlled, double-blind study of niraparib plus abiraterone
acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic
prostate cancer (NCT03748641)

Monday, September 30

12:00 PM CET

Abstract #1412P
Analytical performance of the Resolution-HRD plasma assay used to identify mCRPC patients
with biallelic disruption of DNA repair genes for treatment with niraparib

Monday, September 30

12:00 PM CET

ZYTIGA® (abiraterone acetate)

Poster Presentation

Abstract #95P
Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone in
patients with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study

Monday, September 30

12:00 PM CET

BALVERSA™ (erdafitinib)

Poster Presentations

Abstract #925P
Analysis of response to prior therapies and therapies after treatment with erdafitinib in
fibroblast growth factor receptor (FGFR)-positive patients with metastatic urothelial carcinoma

Monday, September 30

12:00 PM CET

Abstract #926P
Erdafitinib versus available therapies in advanced urothelial cancer: A matching
adjusted indirect comparison

Monday, September 30

12:00 PM CET

Abstract #932P
Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Antitumor Activity
Among Patients with Advanced Urothelial Carcinoma

Monday, September 30

12:00 PM CET

Solid Tumor Portfolio

Poster Presentation

Abstract #488P
Correlation of Progression Free Survival-2 and Overall Survival in Solid Tumors
Saturday, September 28

2:00 PM CET
Source: Johnson, Janssen. 2019. "Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019". Prnewswire.com. https://www.prnewswire.com/news-releases/janssen-to-highlight-depth-of-prostate-cancer-and-solid-tumor-portfolios-with-multiple-data-presentations-at-esmo-2019-300919622.html.

Further Related Content: 
Read: ASCO GU 2018: First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer
Watch: Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris
Titan Clinical Trial Information: NCT02489318
Watch: Interview with Kim Chi, MD - First Results of TITAN
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe